

Small Towns, Big Cities: Rural and Urban Disparities Among Hospitalized Patients With COVID-19 in the Central Savannah River Area

Caroline A. Hamilton,¹ Deepak Ayyala,² David Walsh,³ Christian Bramwell,⁴ Christopher Walker,⁵ Rita Wilson Dib,⁵ Jessica Gosse,⁵ Amber Ladak,¹ Patricia Morissette,³ Arni Rao,¹ Andrew Chao,¹ and Jose Vazquez¹

¹Division of Infectious Disease, Department of Medicine, Augusta University, Augusta, Georgia, USA, ²Department of Population Health Sciences, Augusta University, Augusta, Georgia, USA, ³Division of Hospital Medicine, Department of Medicine, Augusta University, Augusta, Georgia, USA, ⁴Division of Family Medicine, Department of Medicine, Augusta University, Augusta, Georgia, USA, and ⁵Division of Internal Medicine, Department of Medicine, Augusta University, Augusta, Georgia, USA,

Background. There is a lack of data surrounding the impact of coronavirus disease 2019 (COVID-19) among rural and urban communities. This study aims to determine whether there are differences in epidemiologic characteristics and clinical outcomes among individuals with COVID-19 among these communities.

Methods. This was a retrospective analysis of 155 patients admitted to a single-center tertiary academic hospital located in Augusta, Georgia, with a large proportion of hospitalized patients transferred from or residing in rural and urban counties. Hospitalized adult patients were included in the study if they were admitted to AUMC between March 13, 2020, and June 25, 2020, and had a positive polymerase chain reaction test for severe acute respiratory syndrome coronavirus 2 regardless of the presence or absence of symptomatology. Demographics, admission data, and 30-day outcomes were examined overall and by geographical variation.

Results. Urban patients were more likely to be admitted to the general medical floor (P = .01), while rural patients were more likely to require an escalation in the level of care within 24 hours of admission (P = .02). In contrast, of the patients who were discharged or expired at day 30, there were no statistically significant differences in either total hospital length of stay or intensive care unit length of stay between the populations.

Conclusions. There may be many social determinants of health that limit a rural patient's ability to seek prompt medical care and contribute to decompensation within the first 24 hours of admission. This study provides insight into the differences in clinical course among patients admitted from different community settings and when accounting for comorbid conditions.

Keywords. COVID-19; disparities; hospitalized; rural; urban.

Coronavirus disease 2019 (COVID-19) was declared a public health emergency and international pandemic by the World Health Organization (WHO) in January 2020 [1]. Despite the plethora of research, there is still much to be understood about the epidemiology, symptomatology, clinical implications, and outcomes of COVID-19 among different populations. Much of the data published thus far highlight the epidemiology and outcomes of disease in urban cities. Little information exists on how COVID-19 has affected individuals from rural communities [2, 3].

Open Forum Infectious Diseases®2022

The state of Georgia's experience with COVID-19 has been well documented nationally [4, 5], initially because of the sharp increase in cases, along with the numerous "hot spots" described in several rural South Georgia communities, and later on for being one of the first states to lift the shelter-inplace order. Georgia has a unique population with significant health disparities among its urban and rural populations [6]. In fact, this is the reason some refer to the state as being 2 Georgias: Metro Atlanta and "everywhere else." Augusta, Georgia, is located 2.5 hours east of Metro Atlanta and is home to Augusta University Medical Center (AUMC), a public academic medical center that cares for the surrounding urban and rural counties in what is called the Central Savannah River Area (CSRA). The CSRA includes 18 different counties in both Georgia and South Carolina with a total population of >700 000 [7]. During the COVID-19 pandemic, AUMC has taken care of individuals from varying population densities and demographics. The institution has also received a significant number of patient transfers from all over the states of Georgia and South Carolina in order to alleviate the medical

Received 7 September 2021; editorial decision 24 January 2022; accepted 26 January 2022; published online 2 February 2022.

Correspondence: Caroline Hamilton, PA-C, MPH, 1120 15th Street AE 3033, Augusta, GA 30912 (cahamilton@augusta.edu).

[©] The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/ licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com https://doi.org/10.1093/ofid/ofac050

burden on smaller affiliate hospitals and other critical access hospitals.

Previous published work from Augusta University has described the geographical variations associated with COVID-19 incidence and mortality in Georgia using national and state data sets [6]. Their findings suggest that individuals in rural geographical regions, especially non-Hispanic Black American persons, have a higher mortality rate [6]. Evidence from the Centers for Disease Control and Prevention (CDC) indicates that age and the presence of comorbidities increase one's risk for severe COVID-19 disease [8]. As previously stated, there is a higher prevalence of comorbidities among individuals from rural counties when compared with those from urban counties [8]. Our study aims to evaluate the epidemiology, level of care, length of stay, and outcomes of individuals from different geographical regions requiring hospital admission at our institution.

METHODS

Study Design and Participants

Data for this study were obtained by reviewing the patient's electronic medical record (Cerner Power Chart). To be included in the retrospective analysis, patients had to be age 18 and above, be admitted to AUMC between March 13, 2020, and June 25, 2020, and have a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) test regardless of the presence or absence of COVID-19 symptoms. Cases that were high clinical suspicion of COVID-19 but PCR negative were not included in the study. Data were collected using electronic data source forms and transferred to a data collection tool. No interventions were made on subjects included in the retrospective analysis. This study was approved by Augusta University's Institutional Review Board.

Statistical Analysis

We obtained data on patients' county of residence using the address recorded on their medical record. Patients were classified into urban and rural counties based on the classification rules of the US Census Bureau (county populations of ≥50 000 are classified as urban) [9-13]. If the county population was <50 000, then it was considered a rural county. Quantitative variables (age, length of stay, etc.) were summarized using mean (SD) and median (interquartile range), and comparisons were done using the nonparametric Wilcoxon rank-sum test (2 groups) and Kruskal-Wallis analysis of variance test (multiple groups). For categorical variables, absolute and relative abundances within groups were reported. Comparisons between different groups were done using the Fisher exact, and P values were reported. All computations were done using R (version 3.6.1).

RESULTS

This analysis included the first 155 patients admitted to AUMC with a positive SARS-CoV-2 PCR assay between March 13, 2020, and June 25, 2020. Table 1 depicts the general characteristics of the individuals included in the chart review. The median age was 62 years, with a majority of the patients being age 45 years or older (77.42%), African American persons (58.82%), and insured via Medicare and/or Medicaid (54.84%). The 1 Asian patient was removed from comparisons involving race but was included for analysis of the other variables. Of the hospitalized patients, 62 (40.00%) were from a rural county. More

Table 1. Baseline Characteristics

| | No. (%) |
|-----------------------|---------------|
| Total subjects | 155 (100) |
| Demographics | |
| Mean age (SD), y | 59.85 (17.93) |
| Median age (IQR), y | 62 (22.5) |
| Age (by category) | |
| 18–29 y | 9 (5.81) |
| 30–44 y | 26 (16.77) |
| 45–64 y | 55 (35.48) |
| 65+ y | 65 (41.94) |
| Gender | |
| Male | 74 (47.74) |
| Female | 81 (52.26) |
| Race or ethnicity | |
| African American | 90 (58.82) |
| Male | 49 (54.44) |
| Female | 41 (45.56) |
| Age, median (IQR), y | 61 (22.75) |
| White | 52 (33.99) |
| Male | 19 (36.54) |
| Female | 33 (63.46) |
| Age, median (IQR), y | 66 (27.25) |
| Hispanic | 10 (6.54) |
| Male | 5 (50) |
| Female | 5 (50) |
| Age, median (IQR), y | 41 (18.25) |
| Asian | 1 (0.65) |
| Insurance | |
| Commercial | 39 (25.16) |
| Medicare/Medicaid | 85 (54.84) |
| Self-pay | 23 (14.84) |
| Others | 8 (5.16) |
| County type | |
| Rural | 62 (40) |
| Urban | 93 (60) |
| Exposure risk history | |
| Nursing home resident | 41 (26.45) |
| Health care worker | 6 (3.87) |
| Incarcerated | 8 (5.16) |

"Others" insurance includes GA Correctional Health, VA and Workman's Compensation. Race data were obtained using available data in the specified patient demographic. The EMR included Hispanic as a race, although it is generally referred to as an ethnicity. A county was considered rural if the population was <50 000 people.

Abbreviations: EMR, electronic medical record; IQR, interquartile range

than one-quarter (26.45%) of patients admitted to AUMC were nursing home residents (Table 1).

The most common comorbidities were hypertension (107, 69.03%), diabetes mellitus (59, 37.06%), coronary artery disease/congestive heart failure (45, 29.03%), obesity (body mass index 30–39; 55, 35.48%), underlying chronic lung disease (28, 18.06%), and chronic kidney disease of any stage (24, 15.48%) (Table 2). Of the patients admitted, the majority (90.97%) had at least 1 comorbidity present, with African American persons having an average of 2.93 comorbidities and Whites having an average of 2.71 comorbidities. There was a significant difference in the number of comorbidities among African American persons and Hispanic persons as well as between White persons and Hispanic persons. There was no significant difference in the number of comorbidities when comparing rural and urban individuals.

In analyzing admission data, 92 (59.35%) individuals were initially admitted to the general medical floor, 14 (9.03%) were initially admitted to the general medical floor but required transfer to the intensive care unit (ICU) within 24 hours, and 48 (30.97%) were initially directly admitted to the ICU. There was a significant difference among ages (4-way comparison, P = .01) in those admitted to the floor and those admitted to the ICU. In a 3-way comparison, race/ethnicity was not found to be significant among different levels of care on admission, but there was a difference among rural and urban individuals (P = .01). Urban individuals were more likely to be admitted to the floor, while rural individuals were more likely to require escalation of medical care within 24 hours of admission (Table 3).

Table 4 evaluates the 30-day outcomes among the hospitalized population. Of the 155 patients, 78 (50.32%) were discharged home, and 33 (21.29%) were discharged to a skilled nursing facility or long-term acute care center. Seven patients (4.52%) required rehospitalization, and 14 remained hospitalized at day 30 (Table 4). There were no statistically significant differences in discharge disposition, readmissions, total hospital length of stay, ICU length of stay, or mortality rates among rural and urban individuals. Among the 22 (14.19%) expired patients, there were no statistically significant differences in age, number of comorbidities, length of stay, or ICU length of stay among rural and urban individuals (Tables 4 and 5).

DISCUSSION

More than half of all hospitals in the United States are rural hospitals [14]. Frequently understaffed and limited, these institutions serve populations that tend to be older and have less access to care, increased poverty, and numerous comorbidities [15–17]. These characteristics present unique challenges, such as health care disparities and low levels of physician follow-up, which impact rural communities in general but have been augmented during the pandemic [18].

Table 2. Medical History

| Coronary artery disease/congestive heart failure 45 (29.03) Arrythmias 19 (12.26) Hypertension 107 (69.03) Diabetes mellitus 59 (38.06) Obesity BMI 30-39 kg/m² BMI 30-39 kg/m² 16 (10.32) Sickle cell disease 3 (1.94) Connective tissue disease 4 (2.58) Rheumatoid arthritis 2 (1.29) Systemic lupus erythematosus 2 (1.29) Systemic lupus erythematosus 2 (1.29) Current smoker 6 (3.87) Lung disease 2 (1.29) Current smoker 6 (3.87) Lung disease 2 (1.29) Chronic obstructive pulmonary disease 18 (11.61) Asthma 7 (4.52) Interstitial lung disease (any stage) 24 (15.48) Pil/V 1 (0.65) Cerebrovascular accident 2 (3 (14.84) Pulmonary embolism 5 (3.23) Deep vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities by race and ethnicity Mean (SD) Afric | Comorbidities | No. (%) |
|---|--|----------------|
| Arrythmias 19 (12.26) Hypertension 107 (69.03) Diabetes mellitus 59 (38.06) Obesity BMI 30-39 kg/m² Sickle cell disease 3 (1.94) Connective tissue disease 4 (2.58) Rheumatoid arthritis 2 (1.29) Systemic lupus erythematosus 2 (1.29) Systemic lupus erythematosus 2 (1.29) Solid organ transplant 2 (1.29) Current smoker 6 (3.87) Lung disease 2 (1.29) Chronic obstructive pulmonary disease 18 (1161) Asthma 7 (4.52) Interstitial lung disease 2 (1.29) Liver disease 4 (2.58) HIV 1 (0.65) Cerrebrovascular accident 22 (14.84) Pulmonary embolism 5 (3.23) Deep vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities No. (%) 0 14 (9.03) 1 22 (14.84) 2 31 (20.00) 3 40 (25.81) Astima 7 (4.52) | Coronary artery disease/congestive heart failure | 45 (29.03) |
| Hypertension 107 (69.03) Diabetes mellitus 59 (38.06) Obesity 55 (35.48) BMI 30-39 kg/m² 55 (35.48) BMI 240 kg/m² 16 (10.32) Sickle cell disease 3 (1.94) Connective tissue disease 4 (2.58) Rheumatoid arthritis 2 (1.29) Systemic lupus erythematosus 2 (1.29) Taking hydroxychloroquine 3 (1.94) Active malignancy on treatment 7 (4.52) Solid organ transplant 2 (1.29) Current smoker 6 (3.87) Lung disease 28 (18.06) Chronic obstructive pulmonary disease 18 (11.61) Asthma 7 (4.52) Interstitial lung disease (any stage) 24 (15.48) HIV 1 (0.65) Cerebrovascular accident 23 (14.84) Pulmonary embolism 5 (3.23) Deep vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities No. (%) 0 14 (9.03) 1 23 (14.84) | Arrythmias | 19 (12.26) |
| Diabetes mellitus 59 (38.06) Obesity BMI 30–39 kg/m² 55 (35.48) BMI 240 kg/m² 16 (10.32) Sickle cell disease 3 (1.94) Connective tissue disease 4 (2.58) Rheumatoid arthritis 2 (1.29) Systemic lupus erythematosus 2 (1.29) Taking hydroxychloroquine 3 (1.94) Active malignancy on treatment 7 (4.52) Solid organ transplant 2 (1.29) Current smoker 6 (3.87) Lung disease 28 (18.06) Chronic obstructive pulmonary disease 18 (11.61) Asthma 7 (4.52) Interstitial lung disease (any stage) 24 (15.48) HIV 1 (0.65) Cerebrovascular accident 23 (14.84) Pulmonary embolism 5 (3.23) Deep vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities No. (%) 0 14 (9.03) 1 23 (14.84) 2 31 (20.00) 3 40 (25.81) <tr< td=""><td>Hypertension</td><td>107 (69.03)</td></tr<> | Hypertension | 107 (69.03) |
| Obesity BMI 30–39 kg/m² 55 (35.48) BMI 240 kg/m² 16 (10.32) Sickle cell disease 3 (1.94) Connective tissue disease 4 (2.58) Rheumatoid arthritis 2 (1.29) Systemic lupus erythematosus 2 (1.29) Taking hydroxychloroquine 3 (1.94) Active malignancy on treatment 7 (4.52) Solid organ transplant 2 (1.29) Current smoker 6 (3.87) Lung disease 28 (18.06) Chronic obstructive pulmonary disease 18 (11.61) Asthma 7 (4.52) Interstitial lung disease 2 (1.29) Liver disease 4 (2.58) Chronic kidney disease (any stage) 24 (15.48) HIV 1 (0.65) Cerebrovascular accident 23 (14.84) Pulmonary embolism 5 (3.23) Deep vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities No. (%) 0 14 (9.03) 1 2 31 (20.00) 3 2 | Diabetes mellitus | 59 (38.06) |
| BMI 30–39 kg/m² 55 (35.48) BMI ≥40 kg/m² 16 (10.32) Sickle cell disease 3 (1.94) Connective tissue disease 4 (2.58) Rheumatoid arthritis 2 (1.29) Systemic lupus erythematosus 2 (1.29) Taking hydroxychloroquine 3 (1.94) Active malignancy on treatment 7 (4.52) Solid organ transplant 2 (1.29) Current smoker 6 (3.87) Lung disease 28 (18.06) Chronic obstructive pulmonary disease 18 (11.61) Asthma 7 (4.52) Interstitial lung disease 2 (1.29) Liver disease 4 (2.58) Chronic kidney disease (any stage) 24 (15.48) HIV 1 (0.65) Cerebrovascular accident 23 (14.84) Pulmonary embolism 5 (3.23) Deep vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities No. (%) 0 14 (9.03) 1 23 (14.84) 2 31 (20.00) <t< td=""><td>Obesity</td><td></td></t<> | Obesity | |
| BMI ≥40 kg/m² 16 (10.32) Sickle cell disease 3 (1.94) Connective tissue disease 4 (2.58) Rheumatoid arthritis 2 (1.29) Systemic lupus erythematosus 2 (1.29) Taking hydroxychloroquine 3 (1.94) Active malignancy on treatment 7 (4.52) Solid organ transplant 2 (1.29) Current smoker 6 (3.87) Lung disease 28 (18.06) Chronic obstructive pulmonary disease 18 (11.61) Asthma 7 (4.52) Interstitial lung disease 2 (1.29) Liver disease 4 (2.58) Chronic kidney disease (any stage) 24 (15.48) HIV 1 (0.65) Cerebrovascular accident 23 (14.84) Pulmonary embolism 5 (3.23) Deep vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities No. (%) 0 14 (9.03) 1 23 (14.84) 2 31 (20.00) 3 40 (25.81) 4 29 (18.71) 5+ 18 (11.61) <td>BMI 30–39 kg/m²</td> <td>55 (35.48)</td> | BMI 30–39 kg/m ² | 55 (35.48) |
| Sickle cell disease 3 (1.94) Connective tissue disease 4 (2.58) Rheumatoid arthritis 2 (1.29) Systemic lupus erythematosus 2 (1.29) Taking hydroxychloroquine 3 (1.94) Active malignancy on treatment 7 (4.52) Solid organ transplant 2 (1.29) Current smoker 6 (3.87) Lung disease 28 (18.06) Chronic obstructive pulmonary disease 18 (11.61) Asthma 7 (4.52) Interstitial lung disease 2 (1.29) Liver disease 4 (2.58) Chronic obstructive pulmonary disease 18 (11.61) Asthma 7 (4.52) Interstitial lung disease (any stage) 24 (15.48) HIV 1 (0.65) Cerebrovascular accident 23 (14.84) Pulmonary embolism 5 (3.23) Deep vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities No. (%) 0 14 (9.03) 1 23 (14.84) 2 31 (20.00) 3 40 (25.81) 4 | BMI ≥40 kg/m ² | 16 (10.32) |
| Connective tissue disease 4 (2.58) Rheumatoid arthritis 2 (1.29) Systemic lupus erythematosus 2 (1.29) Taking hydroxychloroquine 3 (1.94) Active malignancy on treatment 7 (4.52) Solid organ transplant 2 (1.29) Current smoker 6 (3.87) Lung disease 28 (18.06) Chronic obstructive pulmonary disease 18 (11.61) Asthma 7 (4.52) Interstitial lung disease 2 (1.29) Liver disease 2 (1.29) Der vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities No. (%) 0 14 (9.03) 1 23 (14.84) 2 31 (20.00) 3 40 (25.81) 4 29 (18.71) <tr< td=""><td>Sickle cell disease</td><td>3 (1.94)</td></tr<> | Sickle cell disease | 3 (1.94) |
| Rheumatoid arthritis 2 (1.29) Systemic lupus erythematosus 2 (1.29) Taking hydroxychloroquine 3 (1.94) Active malignancy on treatment 7 (4.52) Solid organ transplant 2 (1.29) Current smoker 6 (3.87) Lung disease 28 (18.06) Chronic obstructive pulmonary disease 18 (11.61) Asthma 7 (4.52) Interstitial lung disease 2 (1.29) Liver disease 2 (1.29) Disease 2 (1.29) Disease 2 (1.29) <td>Connective tissue disease</td> <td>4 (2.58)</td> | Connective tissue disease | 4 (2.58) |
| Systemic lupus erythematosus 2 (1.29) Taking hydroxychloroquine 3 (1.94) Active malignancy on treatment 7 (4.52) Solid organ transplant 2 (1.29) Current smoker 6 (3.87) Lung disease 28 (18.06) Chronic obstructive pulmonary disease 18 (11.61) Asthma 7 (4.52) Interstitial lung disease 2 (1.29) Liver disease (any stage) 24 (15.48) HIV 1 (0.65) Cerebrovascular accident 23 (14.84) Pulmonary embolism 5 (3.23) Deep vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities No. (%) 0 14 (9.03) 1 23 (14.84) 2 31 (20.00) 3 40 (25.81) 4 29 (18.71) | Rheumatoid arthritis | 2 (1.29) |
| Taking hydroxychloroquine 3 (1.94) Active malignancy on treatment 7 (4.52) Solid organ transplant 2 (1.29) Current smoker 6 (3.87) Lung disease 28 (18.06) Chronic obstructive pulmonary disease 18 (11.61) Asthma 7 (4.52) Interstitial lung disease 2 (1.29) Liver disease 4 (2.58) Chronic kidney disease (any stage) 24 (15.48) HIV 1 (0.65) Cerebrovascular accident 23 (14.84) Pulmonary embolism 5 (3.23) Deep vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities No. (%) 0 14 (9.03) 1 23 (14.84) 2 31 (20.00) 3 40 (25.81) 4 29 (18.71) 5+ 18 (11.61) Average comorbidities by race and ethnicity Mean (SD) African American 2.93 (1.61) White .53 African American vs White .53 African American vs Hispanic .00 | Systemic lupus erythematosus | 2 (1.29) |
| Active malignancy on treatment 7 (4.52) Solid organ transplant 2 (1.29) Current smoker 6 (3.87) Lung disease 28 (18.06) Chronic obstructive pulmonary disease 18 (11.61) Asthma 7 (4.52) Interstitial lung disease 2 (1.29) Liver disease 2 (1.29) Liver disease 4 (2.58) Chronic kidney disease (any stage) 24 (15.48) HIV 1 (0.65) Cerebrovascular accident 23 (14.84) Pulmonary embolism 5 (3.23) Deep vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities No. (%) 0 14 (9.03) 1 23 (14.84) 2 31 (20.00) 3 40 (25.81) 4 29 (18.71) 5+ 18 (11.61) Average comorbidities by race and ethnicity Mean (SD) African American 2.93 (1.61) White .53 African American vs White .53 African American vs White .53 | Taking hydroxychloroquine | 3 (1.94) |
| Solid organ transplant 2 (1.29) Current smoker 6 (3.87) Lung disease 28 (18.06) Chronic obstructive pulmonary disease 18 (11.61) Asthma 7 (4.52) Interstitial lung disease 2 (1.29) Liver disease (any stage) 2 (1.21) Dep vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities No. (%) <tr< td=""><td>Active malignancy on treatment</td><td>7 (4.52)</td></tr<> | Active malignancy on treatment | 7 (4.52) |
| Current smoker 6 (3.87) Lung disease 28 (18.06) Chronic obstructive pulmonary disease 18 (11.61) Asthma 7 (4.52) Interstitial lung disease 2 (1.29) Liver disease 4 (2.58) Chronic kidney disease (any stage) 24 (15.48) HIV 1 (0.65) Cerebrovascular accident 23 (14.84) Pulmonary embolism 5 (3.23) Deep vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities No. (%) 0 14 (9.03) 1 23 (14.84) 2 31 (20.00) 3 40 (25.81) 4 29 (18.71) 5+ 18 (11.61) Average comorbidities by race and ethnicity Mean (SD) African American 2.93 (1.61) White .53 African American vs White .53 African American vs White .53 African American vs Hispanic .00 White vs Hispanic .02 | Solid organ transplant | 2 (1.29) |
| Lung disease 28 (18.06) Chronic obstructive pulmonary disease 18 (11.61) Asthma 7 (4.52) Interstitial lung disease 2 (1.29) Liver disease 4 (2.58) Chronic kidney disease (any stage) 24 (15.48) HIV 1 (0.65) Cerebrovascular accident 23 (14.84) Pulmonary embolism 5 (3.23) Deep vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities No. (%) 0 14 (9.03) 1 23 (14.84) 2 31 (20.00) 3 40 (25.81) 4 29 (18.71) 5+ 18 (11.61) Average comorbidities by race and ethnicity Mean (SD) African American 2.93 (1.61) White 2.71 (1.56) Hispanic .00 White .53 African American vs White .53 African American vs Hispanic .00 White vs Hispanic .02 Three-way c | Current smoker | 6 (3.87) |
| Chronic obstructive pulmonary disease 18 (11.61) Asthma 7 (4.52) Interstitial lung disease 2 (1.29) Liver disease 4 (2.58) Chronic kidney disease (any stage) 24 (15.48) HIV 1 (0.65) Cerebrovascular accident 23 (14.84) Pulmonary embolism 5 (3.23) Deep vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities No. (%) 0 14 (9.03) 1 23 (14.84) 2 31 (20.00) 3 40 (25.81) 4 29 (18.71) 5+ 18 (11.61) Average comorbidities by race and ethnicity Mean (SD) African American 2.93 (16.11) White 2.71 (1.56) Hispanic .00 White .53 African American vs White .53 African American vs White .53 African American vs Hispanic .00 White vs Hispanic .02 Thre | Lung disease | 28 (18.06) |
| Asthma 7 (4.52) Interstitial lung disease 2 (1.29) Liver disease 4 (2.58) Chronic kidney disease (any stage) 24 (15.48) HIV 1 (0.65) Cerebrovascular accident 23 (14.84) Pulmonary embolism 5 (3.23) Deep vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities No. (%) 0 14 (9.03) 1 23 (14.84) 2 31 (20.00) 3 40 (25.81) 4 29 (18.71) 5+ 18 (11.61) Average comorbidities by race and ethnicity Mean (SD) African American 2.93 (1.61) White 2.71 (1.56) Hispanic .00 White .53 African American vs White .53 African American vs White .53 African American vs Hispanic .00 White vs Hispanic .02 Three-way comparison .02 Average comorbidities by county type Mean (SD) Rural 2.81 (1. | Chronic obstructive pulmonary disease | 18 (11.61) |
| Interstitial lung disease 2 (1.29) Liver disease 4 (2.58) Chronic kidney disease (any stage) 24 (15.48) HIV 1 (0.65) Cerebrovascular accident 23 (14.84) Pulmonary embolism 5 (3.23) Deep vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities No. (%) 0 14 (9.03) 1 23 (14.84) 2 31 (20.00) 3 40 (25.81) 4 29 (18.71) 5+ 18 (11.61) Average comorbidities by race and ethnicity Mean (SD) African American 2.93 (1.61) White 2.71 (1.56) Hispanic 1.40 (1.58) Comparison of comorbidities between races PValue African American vs White .53 African American vs Hispanic .00 White vs Hispanic .02 Three-way comparison .02 Average comorbidities by county type Mean (SD) Rural 2.81 (1.48) | Asthma | 7 (4.52) |
| Liver disease 4 (2.58) Chronic kidney disease (any stage) 24 (15.48) HIV 1 (0.65) Cerebrovascular accident 23 (14.84) Pulmonary embolism 5 (3.23) Deep vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities No. (%) 0 14 (9.03) 1 23 (14.84) 2 31 (20.00) 3 40 (25.81) 4 29 (18.71) 5+ 18 (11.61) Average comorbidities by race and ethnicity Mean (SD) African American 2.93 (1.61) White 2.71 (1.56) Hispanic 1.40 (1.58) Comparison of comorbidities between races PValue African American vs White .53 African American vs Hispanic .00 White vs Hispanic .02 Three-way comparison .02 Average comorbidities by county type Mean (SD) Rural 2.81 (1.48) Urban 2.68 (1.75) Comparison of comorbidities by county type PValue </td <td>Interstitial lung disease</td> <td>2 (1.29)</td> | Interstitial lung disease | 2 (1.29) |
| Chronic kidney disease (any stage) 24 (15.48) HIV 1 (0.65) Cerebrovascular accident 23 (14.84) Pulmonary embolism 5 (3.23) Deep vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities No. (%) 0 14 (9.03) 1 23 (14.84) 2 31 (20.00) 3 40 (25.81) 4 29 (18.71) 5+ 18 (11.61) Average comorbidities by race and ethnicity Mean (SD) African American 2.93 (1.61) White 2.71 (1.56) Hispanic 1.40 (1.58) Comparison of comorbidities between races PValue African American vs White .53 African American vs Hispanic .00 White vs Hispanic .02 Three-way comparison .02 Average comorbidities by county type Mean (SD) Rural 2.81 (1.48) Urban 2.68 (1.75) Comparison of comorbidities by county type | Liver disease | 4 (2.58) |
| HIV 1 (0.65) Cerebrovascular accident 23 (14.84) Pulmonary embolism 5 (3.23) Deep vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities No. (%) 0 14 (9.03) 1 23 (14.84) 2 31 (20.00) 3 40 (25.81) 4 29 (18.71) 5+ 18 (11.61) Average comorbidities by race and ethnicity Mean (SD) African American 2.93 (1.61) White 2.71 (1.56) Hispanic 1.40 (1.58) Comparison of comorbidities between races PValue African American vs White .53 African American vs White .53 African American vs Hispanic .02 Three-way comparison .02 Average comorbidities by county type Mean (SD) Rural 2.81 (1.48) Urban 2.68 (1.75) Comparison of comorbidities by county type PValue Two-way comparison .49 | Chronic kidney disease (any stage) | 24 (15.48) |
| Cerebrovascular accident 23 (14.84) Pulmonary embolism 5 (3.23) Deep vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities No. (%) 0 14 (9.03) 1 23 (14.84) 2 31 (20.00) 3 40 (25.81) 4 29 (18.71) 5+ 18 (11.61) Average comorbidities by race and ethnicity Mean (SD) African American 2.93 (1.61) White 2.71 (1.56) Hispanic 1.40 (1.58) Comparison of comorbidities between races PValue African American vs White .53 African American vs White .53 African American vs Hispanic .00 White vs Hispanic .02 Three-way comparison .02 Average comorbidities by county type Mean (SD) Rural 2.81 (1.48) Urban 2.68 (1.75) Comparison of comorbidities by county type PValue Two-way comparison <td< td=""><td>HIV</td><td>1 (0.65)</td></td<> | HIV | 1 (0.65) |
| Pulmonary embolism 5 (3.23) Deep vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities No. (%) 0 14 (9.03) 1 23 (14.84) 2 31 (20.00) 3 40 (25.81) 4 29 (18.71) 5+ 18 (11.61) Average comorbidities by race and ethnicity Mean (SD) African American 2.93 (1.61) White 2.71 (1.56) Hispanic 1.40 (1.58) Comparison of comorbidities between races PValue African American vs White .53 African American vs White .53 African American vs White .02 Three-way comparison .02 Average comorbidities by county type Mean (SD) Rural 2.81 (1.48) Urban 2.68 (1.75) Comparison of comorbidities by county type PValue Two-way comparison .49 | Cerebrovascular accident | 23 (14.84) |
| Deep vein thrombosis 6 (3.87) Pregnant 7 (4.52) No. of comorbidities No. (%) 0 14 (9.03) 1 23 (14.84) 2 31 (20.00) 3 40 (25.81) 4 29 (18.71) 5+ 18 (11.61) Average comorbidities by race and ethnicity Mean (SD) African American 2.93 (1.61) White 2.71 (1.56) Hispanic 1.40 (1.58) Comparison of comorbidities between races PValue African American vs White .53 African American vs Hispanic .00 White vs Hispanic .02 Three-way comparison .02 Average comorbidities by county type Mean (SD) Rural 2.81 (1.48) Urban 2.68 (1.75) Comparison of comorbidities by county type PValue Two-way comparison .49 | Pulmonary embolism | 5 (3.23) |
| Pregnant 7 (4.52) No. of comorbidities No. (%) 0 14 (9.03) 1 23 (14.84) 2 31 (20.00) 3 40 (25.81) 4 29 (18.71) 5+ 18 (11.61) Average comorbidities by race and ethnicity Mean (SD) African American 2.93 (1.61) White 2.71 (1.56) Hispanic 1.40 (1.58) Comparison of comorbidities between races PValue African American vs White .53 African American vs White .53 African American vs Hispanic .00 White vs Hispanic .02 Three-way comparison .02 Average comorbidities by county type Mean (SD) Rural 2.81 (1.48) Urban 2.68 (1.75) Comparison of comorbidities by county type PValue Two-way comparison .49 | Deep vein thrombosis | 6 (3.87) |
| No. of comorbidities No. (%) 0 14 (9.03) 1 23 (14.84) 2 31 (20.00) 3 40 (25.81) 4 29 (18.71) 5+ 18 (11.61) Average comorbidities by race and ethnicity Mean (SD) African American 2.93 (1.61) White 2.71 (1.56) Hispanic 1.40 (1.58) Comparison of comorbidities between races PValue African American vs White .53 African American vs Hispanic .00 White vs Hispanic .02 Three-way comparison .02 Average comorbidities by county type Mean (SD) Rural 2.81 (1.48) Urban 2.68 (1.75) Comparison of comorbidities by county type PValue Two-way comparison .49 | Pregnant | 7 (4.52) |
| 0 14 (9.03) 1 23 (14.84) 2 31 (20.00) 3 40 (25.81) 4 29 (18.71) 5+ 18 (11.61) Average comorbidities by race and ethnicity Mean (SD) African American 2.93 (1.61) White 2.71 (1.56) Hispanic 1.40 (1.58) Comparison of comorbidities between races PValue African American vs White .53 African American vs Hispanic .00 White vs Hispanic .02 Three-way comparison .02 Average comorbidities by county type Mean (SD) Rural 2.81 (1.48) Urban 2.68 (1.75) Comparison of comorbidities by county type PValue | No. of comorbidities | No. (%) |
| 1 23 (14.84) 2 31 (20.00) 3 40 (25.81) 4 29 (18.71) 5+ 18 (11.61) Average comorbidities by race and ethnicity Mean (SD) African American 2.93 (1.61) White 2.71 (1.56) Hispanic 1.40 (1.58) Comparison of comorbidities between races PValue African American vs White .53 African American vs Hispanic .00 White vs Hispanic .02 Three-way comparison .02 Average comorbidities by county type Mean (SD) Rural 2.81 (1.48) Urban 2.68 (1.75) Comparison of comorbidities by county type PValue | 0 | 14 (9.03) |
| 2 31 (20.00) 3 40 (25.81) 4 29 (18.71) 5+ 18 (11.61) Average comorbidities by race and ethnicity Mean (SD) African American 2.93 (1.61) White 2.71 (1.56) Hispanic 1.40 (1.58) Comparison of comorbidities between races PValue African American vs White .53 African American vs White .53 African American vs Hispanic .00 White vs Hispanic .00 White vs Hispanic .02 Average comorbidities by county type Mean (SD) Rural 2.81 (1.48) Urban 2.68 (1.75) Comparison of comorbidities by county type PValue Two-way comparison .49 | 1 | 23 (14.84) |
| 3 40 (25.81) 4 29 (18.71) 5+ 18 (11.61) Average comorbidities by race and ethnicity Mean (SD) African American 2.93 (1.61) White 2.71 (1.56) Hispanic 1.40 (1.58) Comparison of comorbidities between races PValue African American vs White .53 African American vs White .53 African American vs Hispanic .00 White vs Hispanic .02 Three-way comparison .02 Average comorbidities by county type Mean (SD) Rural 2.81 (1.48) Urban 2.68 (1.75) Comparison of comorbidities by county type PValue Two-way comparison .49 | 2 | 31 (20.00) |
| 4 29 (18.71) 5+ 18 (11.61) Average comorbidities by race and ethnicity Mean (SD) African American 2.93 (1.61) White 2.71 (1.56) Hispanic 1.40 (1.58) Comparison of comorbidities between races PValue African American vs White .53 African American vs White .53 African American vs Hispanic .00 White vs Hispanic .02 Three-way comparison .02 Average comorbidities by county type Mean (SD) Rural 2.81 (1.48) Urban 2.68 (1.75) Comparison of comorbidities by county type PValue Two-way comparison .49 | 3 | 40 (25.81) |
| 5+18 (11.61)Average comorbidities by race and ethnicityMean (SD)African American2.93 (1.61)White2.71 (1.56)Hispanic1.40 (1.58)Comparison of comorbidities between racesPValueAfrican American vs White.53African American vs Hispanic.00White vs Hispanic.02Three-way comparison.02Average comorbidities by county typeMean (SD)Rural2.81 (1.48)Urban2.68 (1.75)Comparison of comorbidities by county typePValueTwo-way comparison.49 | 4 | 29 (18.71) |
| Average comorbidities by race and ethnicityMean (SD)African American2.93 (1.61)White2.71 (1.56)Hispanic1.40 (1.58)Comparison of comorbidities between racesPValueAfrican American vs White.53African American vs Hispanic.00White vs Hispanic.02Three-way comparison.02Average comorbidities by county typeMean (SD)Rural2.81 (1.48)Urban2.68 (1.75)Comparison of comorbidities by county typePValue | 5+ | 18 (11.61) |
| African American2.93 (1.61)White2.71 (1.56)Hispanic1.40 (1.58)Comparison of comorbidities between racesPValueAfrican American vs White.53African American vs Hispanic.00White vs Hispanic.02Three-way comparison.02Average comorbidities by county typeMean (SD)Rural2.81 (1.48)Urban2.68 (1.75)Comparison of comorbidities by county typePValueTwo-way comparison.49 | Average comorbidities by race and ethnicity | Mean (SD) |
| White2.71 (1.56)Hispanic1.40 (1.58)Comparison of comorbidities between racesPValueAfrican American vs White.53African American vs Hispanic.00White vs Hispanic.02Three-way comparison.02Average comorbidities by county typeMean (SD)Rural2.81 (1.48)Urban2.68 (1.75)Comparison of comorbidities by county typePValueTwo-way comparison.49 | African American | 2.93 (1.61) |
| Hispanic1.40 (1.58)Comparison of comorbidities between racesPValueAfrican American vs White.53African American vs Hispanic.00White vs Hispanic.02Three-way comparison.02Average comorbidities by county typeMean (SD)Rural2.81 (1.48)Urban2.68 (1.75)Comparison of comorbidities by county typePValueTwo-way comparison.49 | White | 2.71 (1.56) |
| Comparison of comorbidities between racesP ValueAfrican American vs White.53African American vs Hispanic.00White vs Hispanic.02Three-way comparison.02Average comorbidities by county typeMean (SD)Rural2.81 (1.48)Urban2.68 (1.75)Comparison of comorbidities by county typePValueTwo-way comparison.49 | Hispanic | 1.40 (1.58) |
| African American vs White.53African American vs Hispanic.00White vs Hispanic.02Three-way comparison.02Average comorbidities by county typeMean (SD)Rural2.81 (1.48)Urban2.68 (1.75)Comparison of comorbidities by county typePValueTwo-way comparison.49 | Comparison of comorbidities between races | <i>P</i> Value |
| African American vs Hispanic.00White vs Hispanic.02Three-way comparison.02Average comorbidities by county typeMean (SD)Rural2.81 (1.48)Urban2.68 (1.75)Comparison of comorbidities by county typePValueTwo-way comparison.49 | African American vs White | .53 |
| White vs Hispanic .02 Three-way comparison .02 Average comorbidities by county type Mean (SD) Rural 2.81 (1.48) Urban 2.68 (1.75) Comparison of comorbidities by county type PValue Two-way comparison .49 | African American vs Hispanic | .00 |
| Three-way comparison .02 Average comorbidities by county type Mean (SD) Rural 2.81 (1.48) Urban 2.68 (1.75) Comparison of comorbidities by county type PValue Two-way comparison .49 | White vs Hispanic | .02 |
| Average comorbidities by county typeMean (SD)Rural2.81 (1.48)Urban2.68 (1.75)Comparison of comorbidities by county typePValueTwo-way comparison.49 | Three-way comparison | .02 |
| Rural 2.81 (1.48) Urban 2.68 (1.75) Comparison of comorbidities by county type P Value Two-way comparison .49 | Average comorbidities by county type | Mean (SD) |
| Urban 2.68 (1.75) Comparison of comorbidities by county type PValue Two-way comparison .49 | Rural | 2.81 (1.48) |
| Comparison of comorbidities by county type P Value Two-way comparison .49 | Urban | 2.68 (1.75) |
| Two-way comparison .49 | Comparison of comorbidities by county type | <i>P</i> Value |
| | Two-way comparison | .49 |

Abbreviation: BMI, body mass index.

Many publications highlight general COVID-19 epidemiologic characteristics, as well as racial disparities [2, 3, 19–25]. However, there are few studies describing the disparities seen between urban and rural settings [2, 19]. One recent study reviewed preliminary outcomes comparing cohorts that received different COVID-19 treatments in a rural hospital [26]. To our knowledge, this is the first study to compare rural and urban

Table 3. Demographics Based on Level of Care Upon Admission

| | Admitted to Floor | Admitted to Floor Then Transferred to ICU Within 24 Hours | Admitted to ICU |
|-------------------------|-------------------|---|-----------------|
| Total subjects, No. (%) | 92 (59.35) | 14 (9.03) | 48 (30.97) |
| Age group | | | |
| 18–29 у | 8 (88.99) | 0 (0.00) | 1 (11.11) |
| 30–44 y | 21 (80.77) | 2 (7.69) | 3 (11.54) |
| 45–64 у | 29 (52.73) | 5 (9.09) | 21 (38.18) |
| 65+ y | 34 (52.31) | 7 (10.77) | 23 (35.38) |
| <i>P</i> value | .01 | .97 | .04 |
| Race | | | |
| African American | 51 (56.67) | 9 (10.00) | 30 (33.33) |
| White | 33 (63.46) | 3 (5.77) | 15 (28.85) |
| Hispanic | 7 (70.00) | 2 (20.00) | 1 (10.00) |
| <i>P</i> value | .62 | .25 | .34 |
| County type | | | |
| Rural | 29 (46.77) | 10 (16.13) | 23 (37.10) |
| Urban | 63 (67.74) | 4 (4.30) | 25 (26.88) |
| <i>P</i> value | .01 | .02 | .22 |
| No. of comorbidities | | | |
| 0 | 11 (78.57) | 0 (0.00) | 3 (21.43) |
| 1 | 19 (82.61) | 3 (13.04) | 1 (4.35) |
| 2 | 18 (58.06) | 4 (12.90) | 9 (29.03) |
| 3 | 23 (57.50) | 1 (2.50) | 15 (37.50) |
| 4 | 15 (51.72) | 4 (13.79) | 10 (34.48) |
| 5+ | 6 (33.33) | 2 (11.11) | 10 (55.56) |
| <i>P</i> value | .02 | .30 | .01 |

Abbreviation: ICU, intensive care unit.

individuals admitted to the same hospital setting with a positive SARS-CoV-2 test, following the same medical therapeutic guidelines for all patients. This study provides valuable insight into the differences among individuals from varying geographical backgrounds in patients receiving similar COVID-19 treatments based on established hospital protocols with guidance from the National Institutes of Health and CDC COVID-19 treatment recommendations [27, 28]. Throughout the duration of the study, patients may have received azithromycin, hydroxychloroquine, remdesivir, tocilizumab, convalescent

Table 4. Day 30 Dispositions

| | Total, No. (%) | Rural, No. (%) | Urban, No. (%) | <i>P</i> Value |
|-----------------------------------|----------------|----------------|----------------|----------------|
| Discharged to home | 78 (50.32) | 33 (53.23) | 45 (48.39) | .62 |
| Discharged to SNF/LTAC | 33 (21.29) | 11 (17.74) | 22 (23.66) | .43 |
| Rehospitalized | 7 (4.52) | 3 (4.84) | 4 (4.30) | 1 |
| Still hospitalized, not in ICU | 7 (4.52) | 4 (6.45) | 3 (3.23) | .44 |
| In ICU—not intubated | 3 (1.94) | 1 (1.61) | 2 (2.15) | 1 |
| In ICU—intub- ated | 4 (2.58) | 3 (4.84) | 1 (1.08) | .30 |
| Expired | 22 (14.19) | 7 (11.29) | 15 (16.13) | .48 |

Abbreviations: ICU, intensive care unit; LTAC, long-term acute care facility; SNF, skilled nursing facility.

plasma, dexamethasone, or any combination of the aforementioned therapeutics based on AUMC's hospital protocols.

The results of our study suggest that among hospitalized individuals in the CSRA, there are no significant differences between the number of comorbidities. However, patients from rural communities were more likely to require an escalation of medical care, resulting in transfer to the ICU within 24 hours after hospital admission. This is particularly useful knowledge as it may help predict which individuals may be at higher risk of early decompensation. Further research should attempt to identify "novel" or "unique" predictors of severity or rapid decompensation that can account for the difference in morbidity between rural- and urban-residing COVID-19 populations.

Limitations

The limitations present in this study are similar to most retrospective chart reviews in that data could only be obtained and utilized from what was documented in the electronic medical record. This analysis included patients who had laboratoryconfirmed testing, regardless of symptomatology. There were 12 subjects who did not possess the classic symptomatology associated with COVID-19 disease but were included in the study due to their positive laboratory testing. The data in this analysis were collected from the first 155 patients who were hospitalized at our facility. Most of these admissions predated the consistent use of dexamethasone and remdesivir and other therapeutic drugs as

Table 5. Characteristics of Discharged and Expired Patients

| | F | Rural | | Urban | |
|------------------------------|--------------|--------------|-------------|--------------|----------------|
| Discharged Patients | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | <i>P</i> Value |
| Total hospital LOS (n = 111) | 11.32 (8.18) | 8.5 (10.00) | 9.61 (8.24) | 7 (11.50) | .10 |
| ICU LOS (n = 73) | 5.36 (7.67) | 0 (9.25) | 3.51 (6.84) | 0 (2.50) | .12 |
| Expired Patients (n = 22) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | <i>P</i> Value |
| Age | 67.86 (8.86) | 67 (7.00) | 69 (18.81) | 66 (24.00) | .94 |
| No. of comorbidities | 3.00 (1.41) | 3 (1.00) | 3.4 (2.06) | 3 (1.50) | .97 |
| Total hospital LOS | 9.71 (8.12) | 7 (6.00) | 9.47 (6.89) | 8 (3.00) | .92 |
| ICU LOS | 7.71 (7.30) | 5 (8.00) | 6.07 (8.28) | 3 (6.50) | .41 |

Total hospital LOS (n = 111) includes the 78 discharged home plus 33 discharged to skilled nursing facilities or long-term acute care facilities. ICU LOS (n = 73) signifies that only 73 of the 111 patients discharged required ICU-level care at some point in their hospital stay.

Abbreviations: ICU, intensive care unit; IQR, interquartile range; LOS, length of stay.

well as vaccines, which could have impacted the outcome data in the early months of the pandemic. Social determinants of health that were not identified in this study may have also impacted patients' clinical outcomes. As this was a single-center study, the results may not be generalizable to other rural communities.

CONCLUSIONS

The COVID-19 pandemic continues to highlight disparities among certain populations. Many of the studies published thus far have been from large urban metropolitan areas [2, 3, 19]. However, patients in rural Georgia communities tend to be older and less educated and to have more comorbidities and disabilities than patients from urban Georgia communities [6, 8]. Our results suggest that special care and medical vigilance should be given to patients from rural communities as they may be more likely to rapidly decompensate within the first 24 hours of admission. An escalation of COVID-19 research targeting rural communities is certainly necessary to better understand the specific impact, pathogenesis, and outcomes of COVID-19 disease in these communities.

Acknowledgments

Financial support. There was no funding associated with this study.

Potential conflicts of interest. All authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Patient consent. This study was approved by the Augusta University Institutional Review Board (IRB) committee. Due to the retrospective nature of the study, patients' written consent was waived, and this was approved by the IRB.

References

 World Health Organization. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel Coronavirus (2019-nCoV). 2020. Available at: https://www.who.int/ news/item/30-01-2020-statement-on-the-second-meeting-of-the-internationalhealth-regulations-(2005)-emergency-committee-regarding-the-outbreak-ofnovel-coronavirus-(2019-ncov. Accessed 11 November 2021.

- Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA 2020; 323:2052–9.
- Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020; 395:1763–70.
- Nicole Chavez AB, Gallagher D. How two funerals helped turn one small Georgia city into a hotspot for coronavirus. CNN. 3 April 2020.
- Solomon A. Some Georgia mayors bristle over governor's decision to lift restrictions amid pandemic. US News & World Report. 4 May 2020.
- Moore JX, Langston ME, George V, Coughlin SS. Epidemiology of the 2020 pandemic of COVID-19 in the state of Georgia: inadequate critical care resources and impact after 7 weeks of community spread. J Am Coll Emerg Physicians Open 2020; 1:527–32.
- Augusta Metro Chamber of Commerce. Regional cities & municipalities. 2021. Available at: https://www.augustametrochamber.com/regional-cities-andmunicipalities. Accessed 17 November 2021.
- Razzaghi H, Wang Y, Lu H, Marshall K, Dowling N. Estimated county-level prevalence of selected underlying medical conditions associated with increased risk for severe COVID-19 illness - United States, 2018. MMWR Morb Mortal Wkly Rep 2020; 69:945–50.
- US Census Bureau, American Community Survey Office. 2010 Census Urban and Rural Classification and Urban Area Criteria. 2020. Available at: https://www. census.gov/programs-surveys/geography/guidance/geo-areas/urban-rural/2010urban-rural.html. Accessed 11 November 2021.
- Georgia Demographics by Cubit. Georgia counties by population. 2020. Available at: https://www.georgia-demographics.com/counties_by_population. Accessed 1 July 2021.
- Georgia Demographics by Cubit. South Carolina counties by population. 2020. Available at: https://www.southcarolina-demographics.com/counties_by_population. Accessed 1 July 2021.
- United States Census Bureau. P2 Hispanic or Latino, and not Hispanic or Latino by race.
 2020 Census State Redistricting Data (Public Law 94-171) summary file. 2021. Available
 at: https://data.census.gov/cedsci/table?g=0400000US13%240500000&y=2020&d=
 DEC%20Redistricting%20Data%20%28PL%2094-171%29&tid=DECENNIALPL2020.
 P2. Accessed 1 July 2021.
- US Census Bureau. Urban areas for the 2020 Census—proposed criteria (2021-03412). National Archives: The Daily Journal of the United States Government. 19 February 2021.
- Health Resources & Services Administration. Rural hospital programs. 2021. Available at: https://www.hrsa.gov/rural-health/rural-hospitals. Accessed 16 November 2021.
- Dandachi D, Reece R, Wang EW, Nelson T, Rojas-Moreno C, Shoemaker DM. Treating COVID-19 in Rural America. J Rural Health. 2021; 37:205–206. doi: 10.1111/jrh.12457.
- Douthit N, Kiv S, Dwolatzky T, Biswas S. Exposing some important barriers to health care access in the rural USA. Public Health 2015; 129:611–20.
- Pender J, Hertz T, Cromartie J, Farrigan T. Rural America at a Glance, 2019 Edition. US Department of Agriculture; 2019.
- Henning-Smith C. The unique impact of COVID-19 on older adults in rural areas. J Aging Soc Policy 2020; 32:396–402.

- Yehia BR, Winegar A, Fogel R, et al. Association of race with mortality among patients hospitalized with coronavirus disease 2019 (COVID-19) at 92 US hospitals. JAMA Netw Open 2020; 3:e2018039.
- Buckner FS, McCulloch DJ, Atluri V, et al. Clinical features and outcomes of 105 hospitalized patients with COVID-19 in Seattle, Washington. Clin Infect Dis 2020; 71:2167–73.
- 21. da Silva JF, Hernandez-Romieu AC, Browning SD, et al. COVID-19 clinical phenotypes: presentation and temporal progression of disease in a cohort of hospitalized adults in Georgia, United States. Open Forum Infect Dis **2021**; 8.
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054–62.
- Turner NA, Pan W, Martinez-Bianchi VS, et al. Racial, ethnic, and geographic disparities in novel coronavirus (severe acute respiratory syndrome coronavirus 2) test positivity in North Carolina. Open Forum Infect Dis 2021; 8.
- 24. Sparling A, Walls M, Mayfield CA, et al. Racial/ethnic disparities in health care setting choice for adults seeking severe acute respiratory syndrome coronavirus 2 testing. Med Care. 2021; 60(1):3–12. doi: 10.1097/ mlr.000000000001654.
- Magesh S, John D, Li WT, et al. Disparities in COVID-19 outcomes by race, ethnicity, and socioeconomic status: a systematic-review and meta-analysis. JAMA Netw Open 2021; 4:e2134147.
- 26. Enzmann MO, Erickson MP, Grindeland CJ, Lopez SMC, Hoover SE, Leedahl DD. Treatment and preliminary outcomes of 150 acute care patients with COVID-19 in a rural health system in the Dakotas. Epidemiol Infect 2020; 148:e124.
- 27. US Department of Health and Human Services. Information on Covid-19 Treatment, Prevention and Research. National Institutes of Health; n.d.
- AU Medical Center. COVID-19 treatment guidelines. 2020. Available at: https:// my.augusta.edu/covid19/. Accessed 18 January 2022.